Swiss drug maker NovImmune has begun a proof-of-concept study to evaluate NI-0801 in patients with primary biliary cirrhosis.
NI-0801 is a fully human monoclonal antibody that neutralises CXCL10 / interferon-gamma-inducible protein-10 (IP-10) chemokine.
Two previous Phase I trials have demonstrated that the drug is safe and well tolerated when given to healthy volunteers.
Principal investigator David Adams said that the therapeutic approach of neutralising CXCL10 / IP-10 with NI-0801 will offer great benefits to the large and therapeutically ill-served primary biliary cirrhosis patient population.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData